Actelion & Nippon Shinyaku v. Lupin: Permanent Injunction Over Selexipag Patents
Actelion Pharmaceuticals and Nippon Shinyaku secured a permanent injunction against Lupin Limited blocking its selexipag injection 1800 mcg/vial product, asserting two US patents covering the compound. The case resolved by consent judgment after 370 days before Delaware District Court Judge Gregory B. Williams.
Permanent injunction blocks Lupin’s selexipag injection in Delaware
Filed on 9 February 2023 in the District of Delaware, this infringement action was brought by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals, Ltd., and Nippon Shinyaku Co., Ltd. against Lupin Limited and Lupin Pharmaceuticals, Inc. The plaintiffs asserted two US patents — US9284280B2 and US8791122B2 — covering selexipag, a prostacyclin receptor agonist used to treat pulmonary arterial hypertension. The accused product was Lupin’s selexipag injection at 1800 mcg/vial.
The case closed on 14 February 2024 — exactly 370 days after filing — with the court entering a consent judgment and order of permanent injunction. The permanent injunction restrains Lupin from commercialising its selexipag injection product in a manner that would infringe the asserted patents. Crucially, the court expressly retained jurisdiction to enforce or supervise performance, meaning the injunction carries ongoing judicial oversight rather than simply closing the matter.
Resolution by consent judgment within approximately one year is consistent with a negotiated settlement between the parties, likely reflecting Lupin’s assessment of infringement risk against two well-scoped selexipag patents. The public record does not disclose financial terms, royalty arrangements, or any agreed launch date for Lupin’s product. The retention of court jurisdiction suggests the parties anticipated the need for ongoing compliance monitoring, which is typical in pharmaceutical injunction orders of this nature.
Filing to settlement in 370 days
370 days — faster than many ANDA-related pharmaceutical patent disputes in Delaware
Permanent injunction granted by consent — court retains supervisory jurisdiction
What a consent judgment means in patent litigation
A consent judgment is a court order entered with the agreement of all parties. Unlike a litigated verdict, it reflects a negotiated resolution memorialised in a binding judicial order. In patent cases, this often signals that the defendant assessed infringement exposure as sufficiently material to warrant settlement rather than risk an adverse ruling at trial. The court’s entry of the order gives it full enforcement authority.
Negotiated resolutionPermanent injunction bars Lupin’s selexipag injection launch
A permanent injunction in a patent infringement consent judgment prohibits the enjoined party — here, Lupin Limited and Lupin Pharmaceuticals — from making, using, selling, or offering for sale the infringing product without authorisation. The injunction over the selexipag injection 1800 mcg/vial product is enforceable by the Delaware District Court, which expressly retained jurisdiction to supervise compliance and enforce performance under the order.
Product blocked from US marketTwo selexipag patents underpin the enforcement action
The plaintiffs asserted US9284280B2 (application no. US14/160641) and US8791122B2 (application no. US13/379531). Both patents relate to selexipag — a compound indicated for pulmonary arterial hypertension. The use of two patents with different application lineages suggests the plaintiffs constructed overlapping protection across compound and potentially formulation or method-of-use dimensions, making design-around strategies more complex for generic entrants.
Layered patent protectionCourt keeps supervisory role post-judgment
The court’s explicit retention of jurisdiction to enforce or supervise performance is a standard but strategically significant feature of pharmaceutical permanent injunctions. It means Actelion and Nippon Shinyaku can return to the Delaware District Court if Lupin is alleged to have breached the injunction terms — without needing to initiate a new action. This creates a durable enforcement mechanism that extends beyond the nominal case closure date of 14 February 2024.
Ongoing enforcement capacityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Actelion Pharmaceuticals US, Inc. | Company | Pharmaceutical IP holders — selexipag innovators holding US9284280B2 and US8791122B2Search in Eureka ↗ |
| Defendant | Lupin Limited | Company | Lupin Limited — Indian generic pharmaceutical manufacturer and its US commercial subsidiarySearch in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Actelion Pharmaceuticals US, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Actelion Pharmaceuticals US, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The verdict language — ‘This court retains jurisdiction to enforce or supervise performance under this Consent Judgment and Order of Permanent Injunction’ — confirms the injunction is both consent-based and judicially supervised. For Actelion and Nippon Shinyaku, this provides a standing enforcement mechanism without re-filing. For Lupin, it means any deviation from agreed terms is immediately actionable in the Delaware District Court, placing the burden of ongoing compliance squarely on the generic manufacturer.
US9284280B2 & US8791122B2 — Selexipag compound and formulation patents
US9284280B2 (application US14/160641) and US8791122B2 (application US13/379531) both protect selexipag — a selective prostacyclin IP receptor agonist approved for the treatment of pulmonary arterial hypertension. The two patents carry different application numbers and lineages, suggesting they cover distinct but complementary aspects of the selexipag IP estate, potentially spanning compound structure, formulation, or therapeutic application. The accused product — selexipag injection 1800 mcg/vial — represents a high-value intravenous dosage form in the PAH treatment market.
Selexipag (marketed as Uptravi) is a commercially significant asset in Actelion’s pulmonary arterial hypertension portfolio, co-developed with Nippon Shinyaku. The layered assertion of two patents with separate application lineages is a strategic hallmark of innovator pharmaceutical enforcement: it forces generic challengers to invalidate or design around multiple independent claims simultaneously. The consent judgment and permanent injunction in this case reinforces the practical enforceability of this estate against ANDA-type generic entry attempts.
Should your team run an FTO against US9284280B2 and US8791122B2?
Any company developing a selexipag-based injectable product, a prostacyclin receptor agonist formulation, or a competing PAH therapy in the 1800 mcg dosage range should treat these two patents as priority FTO targets. The permanent injunction entered in this case confirms the patent holders will enforce — and that US courts will grant injunctive relief. R&D and regulatory teams planning ANDA or 505(b)(2) filings referencing selexipag need a clear-eyed claim-by-claim analysis before advancing to IND or NDA stage.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US9284280B2 and US8791122B2 against your candidate compound or formulation, flagging overlap and identifying prosecution history estoppel relevant to design-around strategies. Eureka’s claim monitoring tools also alert you when continuation applications or related family members publish — critical in a multi-patent estate like this one where new blocking claims may emerge alongside existing enforcement.
Run a freedom-to-operate analysis on US9284280B2 to assess your product’s exposure
Run FTO in Eureka →Similar selexipag and PAH drug patent infringement cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the pulmonary hypertension IP landscape
A consent-based permanent injunction reinforces the strength of the selexipag patent estate and sets a clear precedent for how Actelion and Nippon Shinyaku will defend it.
Innovators are willing to litigate fast and settle hard on selexipag
The 370-day resolution — ending in permanent injunction rather than a licensed entry — signals that the patent holders assessed their IP position as strong enough to compel a blocking outcome. Generic manufacturers targeting selexipag should expect aggressive enforcement and should model injunction risk, not just damages exposure, in any entry strategy.
Dual-patent assertion creates a tougher design-around landscape
Asserting both US9284280B2 and US8791122B2 — with distinct application lineages — suggests overlapping compound and formulation coverage. Competitors and generic entrants need to evaluate both patents independently in any freedom-to-operate analysis. Invalidating one may not be sufficient to clear a path to market.
Actelion v Lupin — key questions answered
The case resolved on 14 February 2024 with a consent judgment and permanent injunction against Lupin Limited and Lupin Pharmaceuticals, Inc. Lupin is barred from commercialising its selexipag injection 1800 mcg/vial product in a manner that infringes the asserted patents. The Delaware District Court retained jurisdiction to enforce or supervise performance.
The plaintiffs asserted two US patents: US9284280B2 (application no. US14/160641) and US8791122B2 (application no. US13/379531). Both patents relate to selexipag, a prostacyclin receptor agonist used in the treatment of pulmonary arterial hypertension.
A consent judgment is a binding court order agreed to by all parties. The accompanying permanent injunction prohibits Lupin from making, selling, or offering for sale its selexipag injection product in a manner that infringes the asserted patents. The Delaware District Court retains jurisdiction to enforce compliance, meaning violations can be addressed without a new lawsuit.
The plaintiffs are Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals, Ltd., and Nippon Shinyaku Co., Ltd. Actelion is part of the Johnson & Johnson group and markets selexipag as Uptravi. Nippon Shinyaku is a Japanese pharmaceutical company that co-developed selexipag and holds IP rights in the compound.
The case was filed on 9 February 2023 and closed on 14 February 2024, a duration of 370 days. Resolution within approximately one year via consent judgment is consistent with an early negotiated settlement, likely reflecting Lupin’s assessment of its infringement exposure under the two asserted selexipag patents.
PatSnap Eureka searches patents and litigation data to answer instantly.